BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 36339710)

  • 1. Identifying tumor immunity-associated molecular features in liver hepatocellular carcinoma by multi-omics analysis.
    Shen Q; He Y; Qian J; Wang X
    Front Mol Biosci; 2022; 9():960457. PubMed ID: 36339710
    [No Abstract]   [Full Text] [Related]  

  • 2. Identification of molecular features correlating with tumor immunity in gastric cancer by multi-omics data analysis.
    He Y; Wang X
    Ann Transl Med; 2020 Sep; 8(17):1050. PubMed ID: 33145269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of tumor mutation burden-associated molecular and clinical features in cancer by analyzing multi-omics data.
    Li M; Gao X; Wang X
    Front Immunol; 2023; 14():1090838. PubMed ID: 36911742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Identification and Analysis of MicroRNAs Combined Biomarkers for Hepatocellular Carcinoma Diagnosis.
    Shi Y; Men J; Sun H; Tan J
    Med Chem; 2022; 18(10):1073-1085. PubMed ID: 35379158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Downregulation of ZC3H13 by miR-362-3p/miR-425-5p is associated with a poor prognosis and adverse outcomes in hepatocellular carcinoma.
    Wu S; Liu S; Cao Y; Chao G; Wang P; Pan H
    Aging (Albany NY); 2022 Mar; 14(5):2304-2319. PubMed ID: 35278064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multi-OMICs data analysis identifies molecular features correlating with tumor immunity in colon cancer.
    Elsayed I; Elsayed N; Feng Q; Sheahan K; Moran B; Wang X
    Cancer Biomark; 2022; 33(2):261-271. PubMed ID: 35213358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive analysis of the MIR4435-2HG/miR-1-3p/MMP9/miR-29-3p/DUXAP8 ceRNA network axis in hepatocellular carcinoma.
    Zhang L; Hu S; Chen J; Ma S; Liu F; Liu C; Gao Y
    Discov Oncol; 2021 Oct; 12(1):38. PubMed ID: 35201491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of prognostic markers for hepatocellular carcinoma based on miRNA expression profiles.
    Wang X; Gao J; Zhou B; Xie J; Zhou G; Chen Y
    Life Sci; 2019 Sep; 232():116596. PubMed ID: 31233760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of lncRNA/circRNA-miRNA-mRNA ceRNA Network as Biomarkers for Hepatocellular Carcinoma.
    Chen S; Zhang Y; Ding X; Li W
    Front Genet; 2022; 13():838869. PubMed ID: 35386284
    [No Abstract]   [Full Text] [Related]  

  • 10. Identification of invasion-metastasis-associated microRNAs in hepatocellular carcinoma based on bioinformatic analysis and experimental validation.
    Lou W; Chen J; Ding B; Chen D; Zheng H; Jiang D; Xu L; Bao C; Cao G; Fan W
    J Transl Med; 2018 Sep; 16(1):266. PubMed ID: 30268144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. C1QTNF1-AS1 regulates the occurrence and development of hepatocellular carcinoma by regulating miR-221-3p/SOCS3.
    Li H; Zhang B; Ding M; Lu S; Zhou H; Sun D; Wu G; Gan X
    Hepatol Int; 2019 May; 13(3):277-292. PubMed ID: 31069760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MiR-30e-3p Influences Tumor Phenotype through
    Gramantieri L; Pollutri D; Gagliardi M; Giovannini C; Quarta S; Ferracin M; Casadei-Gardini A; Callegari E; De Carolis S; Marinelli S; Benevento F; Vasuri F; Ravaioli M; Cescon M; Piscaglia F; Negrini M; Bolondi L; Fornari F
    Cancer Res; 2020 Apr; 80(8):1720-1734. PubMed ID: 32015093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual targeting of PD-L1 and PD-L2 by PCED1B-AS1 via sponging hsa-miR-194-5p induces immunosuppression in hepatocellular carcinoma.
    Fan F; Chen K; Lu X; Li A; Liu C; Wu B
    Hepatol Int; 2021 Apr; 15(2):444-458. PubMed ID: 33219943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MicroRNA profile in HBV-induced infection and hepatocellular carcinoma.
    Wang G; Dong F; Xu Z; Sharma S; Hu X; Chen D; Zhang L; Zhang J; Dong Q
    BMC Cancer; 2017 Dec; 17(1):805. PubMed ID: 29191172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade.
    Bai X; Zhou Y; Yokota Y; Matsumoto Y; Zhai B; Maarouf N; Hayashi H; Carlson R; Zhang S; Sousa A; Sun B; Ghanbari H; Dong X; Wands JR
    J Exp Clin Cancer Res; 2022 Apr; 41(1):132. PubMed ID: 35392977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
    Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
    Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KDM1A Promotes Immunosuppression in Hepatocellular Carcinoma by Regulating PD-L1 through Demethylating MEF2D.
    Wang Y; Cao K
    J Immunol Res; 2021; 2021():9965099. PubMed ID: 34307695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. miR-152-3p impedes the malignant phenotypes of hepatocellular carcinoma by repressing roundabout guidance receptor 1.
    Yin T; Zhao H
    Cell Mol Biol Lett; 2022 Mar; 27(1):22. PubMed ID: 35236289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pivotal role of long non-coding ribonucleic acid-X-inactive specific transcript in regulating immune checkpoint programmed death ligand 1 through a shared pathway between miR-194-5p and miR-155-5p in hepatocellular carcinoma.
    Atwa SM; Handoussa H; Hosny KM; Odenthal M; El Tayebi HM
    World J Hepatol; 2020 Dec; 12(12):1211-1227. PubMed ID: 33442449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identifying biomarkers associated with immunotherapy response in melanoma by multi-omics analysis.
    He Y; Wang X
    Comput Biol Med; 2023 Dec; 167():107591. PubMed ID: 37875043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.